Argatroban in patients with extracorporeal membrane oxygenation—a randomized controlled pilot trial
American Journal of Respiratory and Critical Care Medicine · 01.04.2026 · 212 (4) · 822-826
DOI: 10.1093/ajrccm/aamaf118 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 23.01.2026. Verfasst von Nina Buchtele und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Mitsubishi Tanabe.
Abstract (Originalsprache)
To the Editor Unfractionated heparin (UFH) is the most commonly used anticoagulant during extracorporeal membrane oxygenation (ECMO).1 However, UFH also has several limitations: (1) It requires individualized dosing and close monitoring; (2) its action depends on antithrombin (AT) levels, which may be reduced in some patients; (3) it binds to several proteins, including acute-phase reactants, making it difficult to achieve adequate dosing in patients with hyperinflammatory conditions; and (4) it carries a risk of heparin-induced thrombocytopenia (HIT), type II.2 Direct thrombin inhibitors (DTIs), including argatroban and bivalirudin, may overcome some limitations of UFH while providing similar or greater efficacy. However, the evidence for the use of DTIs in ECMO comes mainly from retrospective studies, which warrants conduct of prospective, randomized trials. This study was an investigator-initiated, prospective, randomized controlled pilot trial conducted in a medical intensive care unit at the Medical University of Vienna/University Hospital Vienna, a tertiary-care facility in Austria.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Intensive Care Unit 13H1, Medical University of Vienna, Vienna, Austria.
- Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Nina Buchtele, Ludwig Traby, Thomas Staudinger
Förderung
- Mitsubishi Tanabe
Zitieren
APA
Buchtele, N., Nagler, B., Schellongowski, P., Quehenberger, P., Hermann, A., Schneeweiß-Gleixner, M., Robak, O., Lobmeyr, E., Schwameis, M., Traby, L., & Staudinger, T. (2026). Argatroban in patients with extracorporeal membrane oxygenation—a randomized controlled pilot trial. American Journal of Respiratory and Critical Care Medicine, 212(4), 822-826. https://doi.org/10.1093/ajrccm/aamaf118
Vancouver
Buchtele N, Nagler B, Schellongowski P, Quehenberger P, Hermann A, Schneeweiß-Gleixner M, et al. Argatroban in patients with extracorporeal membrane oxygenation—a randomized controlled pilot trial. American Journal of Respiratory and Critical Care Medicine. 2026;212(4):822-826. doi:10.1093/ajrccm/aamaf118
BibTeX
@article{Buchtele2026,
author = {Buchtele, Nina and Nagler, Bernhard and Schellongowski, Peter and Quehenberger, Peter and Hermann, Alexander and Schneeweiß-Gleixner, Mathias and Robak, Oliver and Lobmeyr, Elisabeth and Schwameis, Michael and Traby, Ludwig and Staudinger, Thomas},
title = {Argatroban in patients with extracorporeal membrane oxygenation—a randomized controlled pilot trial},
journal = {American Journal of Respiratory and Critical Care Medicine},
year = {2026},
volume = {212},
number = {4},
pages = {822--826},
doi = {10.1093/ajrccm/aamaf118}
}
EUVIMED